Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6470
Provisional Schedule
- Committee meeting:
- 09 September 2025
- Expected publication:
- 28 January 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Alnylam Pharmaceuticals
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Amyloidosis UK
- Cardiomyopathy UK
- Gene People
- Professional groups
- British Cardiovascular Society
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Pfizer (tafamidis) – confidentiality agreement returned, participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2025 | Following further consideration of the scheduling of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy, this topic has now been rescheduled. The committee meeting will now be held on 9 September 2025. |
| 25 April 2025 | Following consideration of the scheduling of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy, this topic has now been rescheduled, and the committee meeting will now be held on 5 November 2025. |
| 12 December 2024 | Referral |
| 25 November 2024 | Invitation to participate |
| 04 October 2024 - 01 November 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6470 |
| 04 October 2024 | In progress. Scoping commencing |
| 15 July 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 15 July 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual